Gasgoo Munich-Is LinkerBot's "price war" on dexterous hands finally materializing?
Gasgoo has learned that LinkerBot recently completed a strategic merger with the team at Jingling Zhikang. The two plan to deepen collaboration on smart bionic hands, rehabilitation aids, and human-machine interaction.
The goal: shift high-performance bionic hands from "custom-made for the few" to "accessible to everyone."
The deal may look modest, but it strikes at the core pain point of China's rehabilitation device industry.
Imported smart bionic hands have long cost between 300,000 and 500,000 yuan, while domestic versions rarely dip below 100,000 yuan. That high price tag has kept robotic products out of the consumer market.
When LinkerBot founder Zhou Yong pledged to slash high-end bionic hand prices to the 30,000–50,000 yuan range—and eventually below 10,000 yuan within three years—it signaled more than a corporate merger. It hinted at a restructuring of the industry's underlying logic.
The "Last Centimeter" of a Booming Sector: Mass Production as the Ultimate Moat
The dexterous hand sector, home to smart bionic prosthetics, is hitting a critical inflection point.
A report by LP Information projects the global market for embodied intelligent robot hands will surge from roughly $267 million in 2025 to $10.35 billion by 2032, expanding at a compound annual growth rate of 70%.
China's market is already staggering in scale, surpassing 50 billion yuan in 2025 with remarkable speed.
LinkerBot has emerged as the sector's hottest target for investors.
Image Source: LinkerBot
Founded in 2023, the company has raced through multiple funding rounds—from seed to Series B+—in just over two years. Backed by top-tier investors like Sequoia China, Ant Group, and the Zhongguancun Science City Fund, it now boasts a valuation of $3 billion.
Its Linker Hand series spans the three mainstream technical approaches: tendon-driven, direct-drive, and linkage. It is the only company globally producing 1,000 high-degree-of-freedom dexterous hands per month, commanding over 80% of that market. By 2026, the company aims to deliver between 50,000 and 100,000 units.
Yet, the ability to mass-produce industrial-grade dexterous hands doesn't automatically translate to success in rehabilitation settings. That gap is exactly what this merger aims to bridge.
"Hardware Mass Production" Meets "Public Rehabilitation": A Precise Fit for Mutual Gaps
Although Jingling Zhikang is a newcomer, its team has built up significant expertise in engineering for rehabilitation scenarios.
Jingling Zhikang may be young, but it has a solid foundation in ergonomic fitting, force-control interaction, and rehabilitation engineering. Co-founder and CEO Song Zhiwei is a seasoned AI veteran who previously held roles at Lenovo, Asus China, and Ingram Micro China, bringing deep experience in strategy, management, and marketing—along with a global perspective.
The R&D team, led by co-founder and CTO Zhu Zitao, draws its core talent from Professor Chen Wenming's lab at Fudan University. They bring mature technology and practical experience in biomechanics, humanoid tactile sensing, exoskeletons, array-motor bionic actuation, natural human-machine force control, human motion modeling, and the commercialization of civilian rehabilitation solutions.
In essence, the merger marries hardware mass production capabilities with the practical know-how needed to serve the public rehabilitation sector.
LinkerBot plugs Jingling Zhikang's biggest gap in manufacturing scale, while Jingling Zhikang opens the door to real-world rehabilitation applications for LinkerBot.
The broader social impact lies in affordability.
According to the China Statistical Yearbook on the Cause of Persons with Disabilities 2024, roughly 5.31 million people in the country hold certificates for physical disabilities. For this group, a smart bionic hand costing hundreds of thousands of yuan is often an impossible dream.
LinkerBot founder Zhou Yong has made it clear: by leveraging in-house R&D across the entire supply chain and large-scale manufacturing, the company will push high-end bionic hand prices down to the 30,000–50,000 yuan range. Within three years, he expects prices to fall below 10,000 yuan.
That's a 90% drop from 300,000 to 30,000 yuan. It's not just a price cut; it marks a critical leap for smart bionic hands from high-end medical devices into the realm of mass-market consumer goods.
Of course, there is still a long way to go between setting a price target and making it a market reality.
Maintaining tactile feedback, comfort, and ease of use while slashing costs is no small feat. Nor is building the channels and service networks required in the highly specialized rehabilitation market. These are the challenges the merged entity must confront.
Still, when a $3 billion leader in dexterous hands decides to enter the public rehabilitation sector through acquisition, the signal is clear: the era of affordable smart bionic hands may arrive sooner than we think.
